PMcardio receives FDA Breakthrough Device Designation — read the full story
Powerful Medical
26. December 2023

European Heart Journal: Clinical Validation Study of the PMcardio OMI AI Model

EHJ International validation

We are proud to announce the publication of a pivotal clinical validation study for PMcardio’s OMI AI Model, “Queen of Hearts,” in the European Heart Journal – Digital Health. This study marks a significant advancement in the application of AI in cardiovascular medicine, specifically in the accurate diagnosis of acute Occlusion Myocardial Infarction (OMI).

Developed using a comprehensive dataset of 18,616 electrocardiograms (ECGs) from 10,543 patients suspected of Acute Coronary Syndrome (ACS), sourced from an international database with angiographically validated outcomes, the “Queen of Hearts” model has been thoroughly evaluated. This evaluation was conducted within an international cohort, comparing the AI model’s performance directly against conventional STEMI criteria and assessments made by seasoned ECG experts.

The majority of ACS cases present without typical ST-elevation, and one-third of Non-ST-elevation myocardial infarction (NSTEMI) patients have an acutely occluded culprit coronary artery, leading to poor outcomes due to delayed identification and management. The “Queen of Hearts” AI model, designed to detect acute OMI on single standard 12-lead ECGs, addresses this challenge.

The “Queen of Hearts” AI model demonstrated an impressive area under the curve (AUC) of 0.938 in identifying OMI, showcasing superior performance with an accuracy of 90.9%, sensitivity of 80.6%, and specificity of 93.7%. These figures surpass the established STEMI criteria and align closely with the proficiency of ECG experts, highlighting the model’s advanced diagnostic capabilities.

The study’s conclusions indicate that the “Queen of Hearts” AI model shows superior accuracy in detecting acute OMI compared to the STEMI criteria. This suggests its potential to improve ACS triage, ensuring appropriate and timely referral for immediate revascularisation.

This publication in the European Heart Journal – Digital Health underscores PMcardio’s dedication to enhancing cardiac care through AI and the potential of AI-powered solutions in transforming the landscape of cardiovascular diagnostics and treatment.

For more details, we invite you to read the full publication available on the European Heart Journal – Digital Health website.

About the Queen of Hearts:

PMcardio’s OMI AI Model, also known as the Queen of Hearts, enables physicians to detect Occlusion Myocardial Infarction (OMI) from any 12-lead ECG regardless of typical ST elevation. The current gold standard misidentifies half of patients in urgent need of treatment for Acute Coronary Occlusion. The Queen of Hearts was developed and clinically validated to improve the early diagnosis of acute obstructive heart attacks in order to improve patient referral and outcomes.

Powerful Medical

Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
About PMcardio:

PMcardio is the market leader in AI-powered diagnostics, addressing the world’s leading cause of death – cardiovascular diseases. The innovative clinical assistant empowers healthcare professionals to detect up to 40 cardiovascular diseases. In the form of a smartphone application, the certified Class IIb medical device interprets any 12-lead ECG image in under 5 seconds to provide accurate diagnoses and individualized treatment recommendations tailored to each patient.

Share this article

Don't miss these

Powerful Medical Receives FDA Breakthrough Device Designation for PMcardio STEMI AI ECG Model

Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announces that its PMcardio STEMI AI ECG model has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This designation recognizes PMcardio as a breakthrough technology for the detection of ST-elevation myocardial infarction (STEMI) and STEMI equivalents—a life-threatening cardiac condition requiring immediate intervention.
ACC_2025

Powerful Medical at ACC 2025: Advancing AI in Cardiovascular Care

We are excited to announce that Powerful Medical will be attending the American College of Cardiology (ACC) 2025 Conference, taking place from March 29th – 31st, 2025, in Chicago, IL, USA. Once again, we have a strong presence at the conference, with multiple papers being presented, underscoring our continued leadership in AI-driven cardiovascular diagnostics.

Join 25,000 healthcare professionals who are already taking advantage of AI